Your Health
ScinnoHub strives to develop innovative small-molecule drugs to treat various types of cancers

Cancer is a major global burden of disease and public health concern. Nearly 1.7 million people in the US are diagnosed with cancer every year, while in China, as many as 3.5 million new cancer patients are diagnosed every year. ScinnoHub strives to develop innovative small-molecule drugs, including protein kinase inhibitors (e.g. cyclin-dependent kinase inhibitors and tyrosine kinase inhibitors) and MAT2A inhibitors as well as radionuclide-drug conjugates to treat various types of cancers.

ScinnoHub is currently developing a novel third-generation reversible BTK inhibitor capable of overcoming drug resistance due to previous treatment with irreversible BTK inhibitors

Lymphoma is a group of over 90 malignant neoplasms of lymphocytes, which is typically classified as non-Hodgkin or Hodgkin lymphomas. Hodgkin lymphoma tends to have favorable prognosis. Non-Hodgkin lymphoma, in contrast, is the most common hematological malignancy worldwide, affecting approximately 1.5 million people and accounting for nearly 3% of cancer diagnoses and deaths. Bruton's tyrosine kinase (BTK) is a key component of the B-cell receptor (BCR) signaling pathway and plays an essential role in B-cell maturation and lymphomagenesis. To date, five irreversible BTK inhibitors have been approved to treat different types of lymphomas.

Lung Cancer & Thyroid Cancer
ScinnoHub is developing a third-generation RET inhibitor to overcome tumor recurrence due to acquired-resistance to treatment of first- and second-generation RET-TKIs
Lung cancer has been the most common cancer globally for the last several decades. In 2018, there was an estimated 2.1 million newly diagnosed lung cancer patients accounting for 12% of the global cancer patients. Estimated 1.8 million patients die of lung cancer every year, accounting for 1 in 5 cancer deaths worldwide. Lung cancer is divided into two histological categories: non-small cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC). NSCLC represents nearly 85% of lung cancers. Treatment of NSCLC includes monotherapy or combined therapy of surgery, radiation therapy, chemotherapy, immune therapy as well as targeted therapy, based on patients’ disease stage, histology and genetic mutation. Surgery is recommended for patients with early stages of NSCLC (Stage I, stage II, and stage IIIA) while targeted therapy is used to treat NSCLC patients in advanced stage (Stage IVB). Tyrosine kinase inhibitors (TKIs) targeting genetic alterations of EGFR, ALK, ROS1, RET, BRAF, MET and NTRK have been approved for the treatment of several subtypes of NSCLC patients.

Thyroid cancer is one of the most common malignancies, accounting for 2% of all cancers. Thyroid cancer is commonly treated with surgery, radioactive iodine ablation and thyrotropin-suppressive therapy with favorable prognosis. However, patients with persistent and recurring thyroid cancers may have poorer prognosis. Targeted therapy with TKIs represents an important therapeutic option for the treatment of advanced thyroid cancer. So far, RET-TKIs, such as Selpercatinib and Pralsetinib, have been approved to treat thyroid cancer.

Prostate Cancer
ScinnoHub is developing long-acting radiolabeled small-molecules for the treatment of prostate cancer

Prostate cancer is the third most common diagnosed malignancy. Although clinically localized prostate cancer can be treated with radical prostatectomy or radiotherapy, the prognosis for metastatic castration-resistant prostate cancer (mCRPC) remains poor. Radioligand therapy, which targets and delivers tumor-killing radiation to cancer cells, is a promising treatment for mCRPC.

Prostate-specific membrane antigen (PSMA) is significantly overexpressed (up to 1000-fold) by prostate cancer cells and its expression level correlates with the stage of cancer and grade of tumor, which enables it to sever as a potential biomarker for targeted radioligand therapy. So far, various PSMA-targeted radioligands have been developed to treat prostate cancer, including 177Lu-PSMA-617 (approved), 177Lu- PSMA I&T (Phase 2) and 177Lu-CTT-1403 (Phase 1).

ScinnoHub is developing long-acting radiolabeled small-molecules for the treatment of prostate cancer. Read more in R&D Platforms.


1. Online Summary of Trends in US Cancer Control Measures.
2. Tasso B, Spallarossa A, Russo E, Brullo C. The Development of BTK Inhibitors: A Five-Year Update. Molecules. 2021;26(23):7411.
3. Lewis WD, Lilly S, Jones KL. Lymphoma: Diagnosis and Treatment. Am Fam Physician. 2020;101(1):34-41.
4. Alexander M, Kim SY, Cheng H. Update 2020: Management of Non-Small Cell Lung Cancer. Lung. 2020;198(6):897-907.

5. Treatment Choices for Non-Small Cell Lung Cancer, by Stage.

6. Valerio L, Pieruzzi L, et al. Targeted Therapy in Thyroid Cancer: State of the Art. Clin Oncol (R Coll Radiol). 2017;29(5):316-324.

7. O'Keefe DS, Bacich DJ, Heston WD. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate. 2004;58(2):200-10.

©2002-2021 ScinnoHub Pharmaceutical Co., Ltd. All rights reserved. Sichuan ICP No. 2021033182-1